S

Sanofi

Global pharma company; vaccines and R&D

Immune Hematology Manager

Full-TimeDeadline 10/16/26
$146.3k - $243.8k
Mid
Bachelor's
Boston, MA, USA
RemoteRemote within the US; territory covers Boston, Massachusetts and Connecticut.
Sales & Account ManagementField Sales

About the job

Requirements
  • A bachelor's degree is required.
  • At least three years of pharmaceutical sales experience is required.
  • A proven record of generating and driving sales results is required.
  • Product launch experience is required.
  • Proficiency in live engagements with healthcare providers and staff is required.
  • Proficiency in Microsoft Office applications is required.
  • Willingness to travel 20% or more of the time is required.
Responsibilities
  • Promote belumosudil to meet or exceed territory sales goals through approved promotional efforts and focused execution.
  • Communicate and provide on-label information about Sanofi Pharmaceuticals’ products to designated targets and accounts.
  • Create clear, comprehensive business plans based on business acumen.
  • Develop knowledge of key customers’ goals and desired clinical outcomes to cultivate partnerships that anticipate and serve customer and patient needs.
  • Develop and maintain strategic relationships with key personnel, healthcare providers, non-healthcare providers, and targeted accounts.
  • Manage and develop territory budgets for customer contacts, promotional programs, and other external expenditures.
  • Analyze sales and market trends to identify current and future business opportunities, and implement a strategic plan of action accordingly.
  • Demonstrate product, disease-state, product-access, and reimbursement expertise.
  • Develop and maintain working relationships with Sanofi Pharmaceuticals team members in Marketing, Managed Care, Analytics, Accounting, Compliance, Legal, and other functions.
  • Maintain knowledge of the Managed Care, group purchasing organizations, Specialty Pharmacy, State Medicaid, and Veterans Affairs selling and reimbursement environment in the assigned geography.
  • Conduct one-on-one, group, and non-personal on-label sales presentations to targeted providers, and prepare and analyze market data to identify customer and market trends.
  • Deliver promotional messages supporting approved product indications through approved channels, including face-to-face and virtual platforms.
  • Use current computer systems to plan, forecast, and review sales activities and optimize resources to meet sales objectives.
  • Accurately and competently manage work hours, sales-call data, customer objectives, communication responses, synchronization, samples when applicable, and expense reporting.
  • Comply with applicable laws, rules, and regulations governing pharmaceutical marketing and promotion and Sanofi.
Desired Qualifications
  • Experience in hematology, oncology, precision medicine, or bone marrow transplant is preferred.
  • Traditional pharmaceutical experience, including field sales, hospital or academic institution sales, or Managed Care experience in the oncology, hematology, or transplant market, is preferred.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...

U.S. Securities and Exchange Commission
Sep 20th, 2026
8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)